A Study of Whether 3 New Oral Formulations of a Strong Pain Killer Release the Same Amount of Drug Into the Body as the Marketed Medication
Phase 1
Completed
- Conditions
- Pain
- Interventions
- Drug: MR3XXXDrug: MRXXXDrug: MR1XXXDrug: MR2XXX
- First Posted Date
- 2015-05-18
- Last Posted Date
- 2017-08-31
- Lead Sponsor
- Mundipharma Research Limited
- Target Recruit Count
- 32
- Registration Number
- NCT02446561
- Locations
- 🇬🇧
BioKinetic Europe Ltd, Belfast, United Kingdom
An Assessment of Buprenorphine Transdermal Delivery System (BTDS) Patch Adhesion
Phase 1
Completed
- Conditions
- Pain
- Interventions
- Drug: BTDS
- First Posted Date
- 2015-05-01
- Last Posted Date
- 2016-02-09
- Lead Sponsor
- Mundipharma Research Limited
- Target Recruit Count
- 40
- Registration Number
- NCT02431624
- Locations
- 🇬🇧
BioKinetic Europe Ltd, Belfast, United Kingdom
A Pharmacokinetic/Pharmacodynamic Inhaler Comparison Study in Healthy Volunteers
Phase 1
Completed
- Conditions
- Asthma
- Interventions
- Drug: Fluticasone/formoterol BAIDrug: Fluticasone/formoterol PMDI with spacerDrug: Fluticasone/formoterol PMDI without spacerDrug: Fluticasone/formoterol PMDI without spacer low dose
- First Posted Date
- 2015-03-31
- Last Posted Date
- 2015-09-28
- Lead Sponsor
- Mundipharma Research Limited
- Target Recruit Count
- 125
- Registration Number
- NCT02403713
Bioequivalence and Adhesion Comparison of Buprenorphine Patches
- First Posted Date
- 2014-10-20
- Last Posted Date
- 2016-02-09
- Lead Sponsor
- Mundipharma Research Limited
- Target Recruit Count
- 104
- Registration Number
- NCT02268422
Flutiform® Compared With Seretide® in the Treatment of COPD
Phase 2
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- First Posted Date
- 2014-07-21
- Last Posted Date
- 2017-03-28
- Lead Sponsor
- Mundipharma Research Limited
- Target Recruit Count
- 923
- Registration Number
- NCT02195375
A Dose Proportionality and Bioavailability Assessment of Buprenorphine Transdermal Delivery System Second Generation Patches
Phase 1
Completed
- Conditions
- Pain
- Interventions
- Drug: Second generation BTDS patchDrug: First generation BuTrans patch
- First Posted Date
- 2014-06-10
- Last Posted Date
- 2014-09-30
- Lead Sponsor
- Mundipharma Research Limited
- Target Recruit Count
- 20
- Registration Number
- NCT02160067
- Locations
- 🇬🇧
Quotient Clinical Ltd, Nottingham, United Kingdom
A Study to Assess How the Body Processes a Strong Painkiller When it is Given Alongside a Drug That Counteracts the Side Effects of Strong Painkillers in a Fasted and Fed State.
Phase 1
Completed
- Conditions
- Pain
- Interventions
- Drug: 4 mg 12 hourly capsule - strong pain killer fedDrug: 4 mg 12 hourly capsule - strong pain killer fastedDrug: 4 mg 12 hourly capsule strong painkiller with antagonist fedDrug: 12 hourly capsule strong painkiller with antagonist fasted)
- First Posted Date
- 2014-05-08
- Last Posted Date
- 2014-06-27
- Lead Sponsor
- Mundipharma Research Limited
- Target Recruit Count
- 16
- Registration Number
- NCT02133820
- Locations
- 🇬🇧
Quotient Clinical Limited, Nottingham, Nottinghamshire, United Kingdom
A Study of Whether 2 New Oral Formulations of a Strong Pain Killer Release the Same Amount of Drug Into the Body as the Marketed Medication
Phase 1
Completed
- Conditions
- Pain
- Interventions
- Drug: Active comparator MR2XXXDrug: MR1XXXDrug: MRXXXDrug: MRXXX and MR1XXX
- First Posted Date
- 2014-03-18
- Last Posted Date
- 2015-09-28
- Lead Sponsor
- Mundipharma Research Limited
- Target Recruit Count
- 32
- Registration Number
- NCT02089581
- Locations
- 🇬🇧
Biokinetic, Belfast, United Kingdom
Knemometry Study to Compare the Systemic Safety of Flutiform pMDI, Fluticasone pMDI and Beclometasone Autohaler in Paediatric Subjects Aged 5 to Less Than 12 Years.
Phase 2
Completed
- Conditions
- Mild Persistent Asthma
- Interventions
- Drug: Beclometasone Autohaler 50 ug (2 puffs bid)
- First Posted Date
- 2014-02-14
- Last Posted Date
- 2018-10-24
- Lead Sponsor
- Mundipharma Research Limited
- Target Recruit Count
- 48
- Registration Number
- NCT02063139
- Locations
- 🇩🇰
Asthma and Allergy Children's Clinic, Randers, Denmark
A Study to Show That Flutiform is Well Tolerated and Effective in the Treatment of COPD
Phase 3
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- First Posted Date
- 2013-09-19
- Last Posted Date
- 2018-10-24
- Lead Sponsor
- Mundipharma Research Limited
- Target Recruit Count
- 1767
- Registration Number
- NCT01946620
© Copyright 2025. All Rights Reserved by MedPath